In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression

Abstract excerpt

The COVID-19 pandemic caused by SARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 entry. Recent studies have suggested that patients with hypertension and diabetes treated with ACE inhibitors (ACEIs) or angiotensin receptor blockers have a higher risk of COVID-19 infection as these drugs could upregulate ACE2, motivating the study of ACE2...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to COVID-19 Clinical Research Studies
• Share to PARP inhibition in cancer therapy
• Share to SARS-CoV-2 and COVID-19 Research